MedDRA preferred term

Internal haemorrhage: adverse event reports recording this term

11,297 reports to FDA record it, 2009–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

11,297
reports recording the term: 0.1% of all reports; 528
reports, 12 months to June 2026: 550 in the 12 months before; 98.2%
marked serious by the reporter: 57.4% across all reports; 18.2%
record death among outcomes, as reported: 9.1% across all reports

"Internal haemorrhage" is a MedDRA preferred term recorded in 11,297 adverse event reports received by FDA, 0.1% of the database, from June 2009 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

528 reports recorded it in the 12 months to June 2026, close to the 550 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 98.2% are marked serious, 18.2% include death among the outcomes and 62.8% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Xarelto, Aspirin and Eliquis. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Xarelto	Factor Xa inhibitor	3,520	2.6%
Aspirin	Nonsteroidal anti-inflammatory drug	668	0.9%
Eliquis	Factor Xa inhibitor	600	0.5%
Humira	—	468	0.1%
Acetylsalicylic Acid	—	420	1.7%
Pradaxa	Direct thrombin inhibitor	370	0.6%
Plavix	P2Y12 platelet inhibitor	313	1%
Coumadin	—	229	1%
Ambrisentan	Endothelin receptor antagonist	168	0.3%
Revlimid	Thalidomide analog	139	0%
Ofev	Kinase inhibitor	131	0.5%
Opsumit	Endothelin receptor antagonist	131	0.3%
Imbruvica	Kinase inhibitor	130	0.2%
Apixaban	Factor Xa inhibitor	115	0.2%
Enbrel	Tumor necrosis factor blocker	114	0%
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose	—	112	0.2%
Bayer Low Dose	Nonsteroidal anti-inflammatory drug	109	2.9%
Rinvoq	Janus kinase inhibitor	105	0.1%
Jakafi	Janus kinase inhibitor	97	0.2%
Warfarin	Vitamin K antagonist	91	0.4%
Adempas	Soluble guanylate cyclase stimulator	83	0.4%
Remodulin	Prostacycline vasodilator	81	0.2%
Entresto	Angiotensin 2 receptor blocker	79	0.1%
Skyrizi	Interleukin-23 antagonist	78	0.1%
Lovenox	Low molecular weight heparin	76	0.5%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Factor Xa inhibitor	4,281	1.3%	0.2%
Nonsteroidal anti-inflammatory drug	1,084	0.2%	0%
Kinase inhibitor	655	0.1%	0%
P2Y12 platelet inhibitor	473	0.5%	0.3%
Endothelin receptor antagonist	392	0.2%	0.2%
Direct thrombin inhibitor	370	0.6%	0%
Prostacycline vasodilator	262	0.2%	0.2%
Janus kinase inhibitor	258	0.1%	0%
Thalidomide analog	178	0%	0%
Tumor necrosis factor blocker	174	0%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%8

2 to 110.3%32

12 to 170.3%35

18 to 446.4%723

45 to 6418.7%2,114

65 to 7418.7%2,116

75 and over21.8%2,462

Age not given33.7%3,807

Patient sex

Female45.5%5,144

Male44.2%4,989

Not given10.3%1,164

Grey bar: all 20,646,523 reports in the database. 77.9% of these reports give the United States as the country.

Questions about "Internal haemorrhage"

What does "Internal haemorrhage" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record internal haemorrhage?

11,297 reports through June 2026 (0.1% of all reports), 528 of them in the latest 12 months.

Which drugs appear most often in these reports?

Xarelto (3,520), Aspirin (668), Eliquis (600), Humira (468) and Acetylsalicylic Acid (420). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.